Please ensure Javascript is enabled for purposes of website accessibility

Why Quidel Stock Soared 27% in March While the Market Plunged

By Beth McKenna - Updated Apr 8, 2020 at 2:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The coronavirus pandemic sank the market last month, but it was directly responsible for lifting shares of this healthcare diagnostics company.

What happened

Shares of Quidel (QDEL), which manufactures diagnostic healthcare products, jumped 26.6% in March, according to data from S&P Global Market Intelligence

For context, last month, the S&P 500 index returned negative 12.4%. The market sell-off was due to investors' concerns about the negative economic impact of the coronavirus pandemic.

This month, Quidel stock has sunk 10.5% through April 7, compared to the broader market's 2.9% gain. So far in 2020, it's up 16.7%, whereas the S&P 500 has returned negative 17.2%.

A gloved hand holding a vial of blood labeled "coronavirus" with "no" checked (instead of "yes")

Image source: Getty Images.

So what

We can attribute Quidel stock's robust performance last month to investor enthusiasm about its sales prospects after the company's March 17 announcement that it had received emergency use authorization from the U.S. Food and Drug Administration (FDA) to market its coronavirus test, the Lyra SARS-CoV-2 Assay. Shares popped 26.2% following this announcement. 

"Emergency Use Authorization for our Lyra SARS-CoV-2 Assay allows Quidel to join the global fight against the COVID-19 outbreak by providing healthcare workers in highly complex laboratories with a fast, accurate tool to diagnose patients infected with the novel coronavirus," CEO Douglas Bryant said in the press release. He went on to say that the company developed the assay in "mere weeks."

Then on March 26, Quidel announced that its coronavirus test had received the CE Mark, which opened the door to sales in Europe, as well as in other countries that accept the CE Mark, and that the company had received authorization from Health Canada to sell the test in Canada. Shares jumped 10.3%, which is four percentage points greater than the market's big gain that day.

Now what

No doubt, investors will get an update on how sales of the Lyra coronavirus test are going when Quidel reports its quarterly results. The company hasn't yet announced a date, but it should be sometime in early to mid May.

Beth McKenna has no position in any of the stocks mentioned. The Motley Fool recommends Quidel. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Quidel Corporation Stock Quote
Quidel Corporation
QDEL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.